A Preview Of Travere Therapeutics's Earnings
Portfolio Pulse from Benzinga Insights
Travere Therapeutics (NASDAQ:TVTX) is set to announce its quarterly earnings on October 31, 2024. Analysts estimate an EPS of $-0.70. The company previously beat EPS estimates but saw a share price drop. Analysts rate it as a 'Buy' with a price target of $22.17, indicating a potential 20.69% upside. Travere's revenue growth is 68.08%, but it lags behind peers. The company faces challenges with a high debt-to-equity ratio and negative ROE.
October 30, 2024 | 9:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Travere Therapeutics is expected to announce its earnings with an estimated EPS of $-0.70. Analysts rate it as a 'Buy' with a price target of $22.17, suggesting a potential 20.69% upside. Despite positive revenue growth, the company faces challenges with high debt and negative ROE.
The upcoming earnings announcement is crucial for Travere Therapeutics, with analysts expecting an EPS of $-0.70. The 'Buy' rating and price target suggest potential upside, but past performance shows that even beating estimates can lead to a share price drop. The company's high debt and negative ROE are significant concerns that could impact investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100